Cue Biopharma reports Q1 EPS (17c), consensus (15c)

Reports Q1 revenue $0.4M, consensus $1.27M. “We made notable and encouraging progress during the first quarter of 2025 and believe we are well positioned to further our corporate objectives,” said Daniel Passeri, chief executive officer of Cue Biopharma (CUE). “We believe the strategic collaboration with Boehringer Ingelheim for CUE-501 combined with our capital raise, places us in a position of strength to advance CUE-401 toward the clinic while exploring additional portfolio optimization and partnering opportunities.”